Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

dc.contributor.author	Planz, Oliver
dc.date.accessioned	2024-03-13T15:09:45Z
dc.date.available	2024-03-13T15:09:45Z
dc.date.issued	2023
dc.identifier.issn	2589-5370
dc.identifier.uri	http://hdl.handle.net/10900/151917
dc.language.iso	en	en
dc.publisher	Amsterdam : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.eclinm.2023.102237
dc.subject.ddc	610	de_DE
dc.title	Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240124000000_00567
utue.personen.roh	Rohde, Gernot
utue.personen.roh	Stenglein, Stephan
utue.personen.roh	Prozesky, Hans
utue.personen.roh	Manudhane, Ganesh
utue.personen.roh	Sandulescu, Oana
utue.personen.roh	Bauer, Martin
utue.personen.roh	Overend, Tim
utue.personen.roh	Koch, Winfried
utue.personen.roh	Neuschwander, Dennis
utue.personen.roh	Planz, Oliver
utue.personen.roh	Torres, Antoni
utue.personen.roh	Witzenrath, Martin
dcterms.isPartOf.ZSTitelID	Eclinicalmedicine	de_DE
dcterms.isPartOf.ZS-Issue	Article 102237	de_DE
dcterms.isPartOf.ZS-Volume	65	de_DE
utue.fakultaet	Universität Tübingen (ohne Fakultätsangabe)